Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 10,462 shares at $78.50 ($823K) on 2026-06-17, disclosed to the SEC on 2026-06-22.
Scheduled sale ($823k) by Executive VP AND CLO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $78.50 | 1,703 | $134K | 16.2% |
| 2 | $78.50 | 6,600 | $518K | 63.0% |
| 3 | $79.24 | 1,850 | $147K | 17.8% |
| 4 | $79.25 | 309 | $24K | 3.0% |
| Total | $78.65 avg | 10,462 | $823K | 100% |
| Filing → |
| PTCT | SELL | 2026-05-19 | $203K | — | Filing → |
| PTCT | SELL | 2026-05-12 | $280K | — | Filing → |
| PTCT | SELL | 2026-04-08 | $157K | — | Filing → |